Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Ershen Pill is a traditional Chinese medicine formulation derived from the original "Ershen Pill" (ESP). It is primarily studied for its effects on Pi (Spleen)-Shen (Kidney) yang deficiency-induced diarrhea, a syndrome recognized in traditional Chinese medicine. In preclinical studies using rat models, extracts of the pill have been shown to alleviate symptoms such as diarrhea and weight loss by improving aquaporin-3 (AQP3) synthesis in the colon. This suggests that its mechanism involves modulation of water transport and intestinal function via upregulation of AQP3 expression. The formulation typically contains multiple herbal ingredients, but specific composition details for "Modified Ershen Pill" are not provided in available sources[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Modified Ershen Pill.